In addition, BBR suppresses the toll-like receptor 9 (TLR9)-myeloid differentiation factor 88 (MyD88)–nuclear factor kappa-B (NF-κB) pathway and partly reverses doxorubicin (Dox)-exacerbated breast cancer metastasis (Zheng et al., 2021). The gene discussed is TLR9; the disease is breast carcinoma.